

Version 3.0      Revision Date: 15.01.2018      SDS Number: 12359      Date of last issue: -  
Date of first issue: 15.01.2018

---

## SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

### 1.1 Product identifier

#### NEXIUM TABLETS

Details of the supplier of the safety data sheet : ASTRAZENECA PTY LTD      Emergency Telephone  
PO Box 131      +44 (0) 1235 239 670  
66 Talavera Rd, North Ryde  
NSW 2113  
AUSTRALIA  
+61 2 9978 3500  
  
SafetyDataSheets.AlderleyPark@astrazeneca.com

#### Alternative Names

Esomeprazole gastro-resistant tablets  
CAS No. : Not applicable.

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Symptomatic treatment of gastro-oesophageal reflux disease (GERD)

---

## SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification

Skin sensitisation : Category 1

Chronic aquatic toxicity : Category 3

#### GHS label elements

Hazard pictograms :



Signal word : Warning

Hazard statements : H317 May cause an allergic skin reaction.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves.  
**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of soap and water.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.

Version 3.0      Revision Date: 15.01.2018      SDS Number: 12359      Date of last issue: -  
 Date of first issue: 15.01.2018

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

Hazardous components which must be listed on the label:

Esomeprazole Magnesium Trihydrate

**Other hazards which do not result in classification**

May cause irritation to skin, eyes and respiratory system.

See Section 11.

The product may form flammable dust clouds in air, if dust from crushed tablets is allowed to accumulate.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Hazardous components**

Chemical name	CAS-No.	Concentration (% w/w)
Celluloses	9004-34-6	70 -71
Esomeprazole Magnesium Trihydrate	217087-09-7	5 -8

**SECTION 4. FIRST AID MEASURES**

- If inhaled : Remove patient from exposure.  
Obtain medical attention if ill effects occur.
- In case of skin contact : Wash skin with soap and water.
- In case of eye contact : Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 minutes.  
Obtain medical attention if ill effects remain.
- If swallowed : Wash out mouth with water and give 200-300ml of water to drink.  
Obtain medical attention if ill effects occur.  
Do NOT induce vomiting as a First-Aid measure.
- Most important symptoms and effects, both acute and delayed : Refer to sections 2 and 11  
May cause an allergic skin reaction.
- Notes to physician : Symptomatic treatment and supportive therapy as indicated.  
For further information consult the prescribing information.

**SECTION 5. FIREFIGHTING MEASURES**

- Suitable extinguishing media : water spray, foam, dry powder or CO<sub>2</sub>.
- Unsuitable extinguishing media : Avoid high pressure media which could cause the formation of a potentially explosible dust-air mixture.

# SAFETY DATA SHEET



Version 3.0      Revision Date: 15.01.2018      SDS Number: 12359      Date of last issue: -  
Date of first issue: 15.01.2018

Specific hazards during firefighting : If involved in a fire, it may burn and emit noxious and toxic fumes.

Special protective equipment for firefighters : A self contained breathing apparatus and suitable protective clothing should be worn in fire conditions.  
Prevent fire extinguishing water from contaminating surface water or the ground water system.

## SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Ensure suitable personal protection during removal of spillages.  
Avoid dispersal of dust in the air.

Environmental precautions : Prevent entry into drains, sewers or watercourses.  
Collect spillage.

Methods and materials for containment and cleaning up : Avoid dust generation.  
Transfer spilled tablets to a suitable container for disposal.  
Wash the spillage area with water.  
Avoid release to the environment.

## SECTION 7. HANDLING AND STORAGE

Advice on safe handling : Avoid contact with skin and eyes.  
Wear protective gloves.  
See Section 8.  
Minimize dust generation and accumulation.  
The product may form flammable dust clouds in air, if dust from crushed tablets is allowed to accumulate.

Conditions for safe storage : Keep container tightly closed.  
Protect from light.

Recommended storage temperature : < 30 °C

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Celluloses	9004-34-6	TWA	10 mg/m <sup>3</sup>	AU OEL
		Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica		
		TWA	10 mg/m <sup>3</sup>	ACGIH
Esomeprazole Magnesium Trihydrate	217087-09-7	TWA	0.1 mg/m <sup>3</sup>	COM; HYG

**Engineering measures** : The specific controls will depend on local circumstances and should be based on the risk assessment. Appropriate

Version	Revision Date:	SDS Number:	Date of last issue: -
3.0	15.01.2018	12359	Date of first issue: 15.01.2018

---

controls to reduce exposure may include engineering controls, for example ventilation, procedural controls and the use of personal protection equipment.

Prevent entry into drains, sewers or watercourses.  
See Section 6 for environmental precautions.

#### Personal protective equipment

- Respiratory protection : Use a negative pressure air purifying respirator (half face mask) with filter class P3 if the risk assessment does not support the selection of other protection.
- Eye protection : Use safety glasses to protect against direct contact with the product if the risk assessment does not support the selection of other protection.
- Skin and body protection : Use impervious clothing to protect against direct contact with the product if the risk assessment does not support the selection of other protection. Use impervious protective gloves to protect against direct contact with the product. If the product is dissolved or wetted use a glove material that is resistant to the solvent/liquid.
- Protective measures : Decisions about whether the use of personal protective equipment (PPE) is appropriate as part of the control strategy should be based on the workplace risk assessment and should take account of local legislative requirements for selection and use. There are multiple factors that will affect the specific requirements such as amount and concentration of the material, duration of exposure, frequency of exposure, external environmental conditions, the task, the user etc. All the information above should not be used in isolation and should be considered in the context of the workplace risk assessment on a case by case basis.

The recommended personal protective equipment (PPE) is based on preventing the potential adverse health effects from exposure to the active pharmaceutical ingredient (API). The risk of exposure to the API in the formulation/product needs to be taken into consideration.

---

#### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

- Appearance : coated tablets
- Colour : 20 mg-light pink, 40 mg-pink
- Odour : No data available
- Odour Threshold : No data available

# SAFETY DATA SHEET



Version 3.0      Revision Date: 15.01.2018      SDS Number: 12359      Date of last issue: -  
Date of first issue: 15.01.2018

---

pH : No data available

Melting point/range : No data available

Initial boiling point and boiling range : Not applicable

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Solubility(ies)

    Water solubility : No data available

    Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

    Viscosity, dynamic : Not applicable

    Viscosity, kinematic : Not applicable

Explosive properties : No data available

Oxidizing properties : Not applicable

---

## SECTION 10. STABILITY AND REACTIVITY

Reactivity : No known reactivity hazard under normal conditions.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : None known.

Version	Revision Date:	SDS Number:	Date of last issue: -
3.0	15.01.2018	12359	Date of first issue: 15.01.2018

---

Conditions to avoid	:	No conditions producing hazardous situations known.
Incompatible materials	:	Acids , decomposes
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

## SECTION 11. TOXICOLOGICAL INFORMATION

### 11.1 Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
---------------------	---	--

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Acute oral toxicity	:	Evident toxicity with mortality in rats at a dose of: 480 mg/kg Assessment: The component/mixture is moderately toxic after single ingestion. Remarks: By analogy with Esomeprazole
Acute inhalation toxicity	:	Remarks: May cause effects as described under single exposure.(STOT)
Acute dermal toxicity	:	Remarks: No information available.

### 11.2 Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Result: Mild skin irritation

### 11.3 Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Remarks: May cause eye irritation.  
May cause conjunctivitis.

### 11.4 Respiratory or skin sensitisation

#### **Skin sensitisation**

May cause an allergic skin reaction.

Version	Revision Date:	SDS Number:	Date of last issue: -
3.0	15.01.2018	12359	Date of first issue: 15.01.2018

---

**Respiratory sensitisation**

Not classified based on available information.

**Components:****Esomeprazole Magnesium Trihydrate:**

Result: May cause sensitisation by skin contact.

Remarks: Omeprazole:

It is an extreme skin sensitiser in animal tests.

Many cases of occupational skin sensitisation have been reported.

**Chronic toxicity****11.5 Germ cell mutagenicity**

Not classified based on available information.

**Components:****Esomeprazole Magnesium Trihydrate:**

Germ cell mutagenicity - Assessment : The substance is not considered to be genotoxic.

**11.6 Carcinogenicity**

Not classified based on available information.

**Components:****Esomeprazole Magnesium Trihydrate:**

Carcinogenicity - Assessment : The substance is not considered to be carcinogenic.

**11.7 Reproductive toxicity**

Not classified based on available information.

**Components:****Esomeprazole Magnesium Trihydrate:**

Reproductive toxicity - Assessment : There is no evidence of a teratogenic potential or any other adverse effects on reproductive function.

**11.8 STOT - single exposure**

Not classified based on available information.

**Components:****Esomeprazole Magnesium Trihydrate:**

Exposure routes: Oral, Inhalation

Remarks: May cause nausea and vomiting.

Rare cases of hypersensitivity (including allergic reactions) and CNS-effects (including dizziness and muscle jerks) have been reported in patients.

Exposure routes: Inhalation

Remarks: Dust may be irritant to the respiratory tract.

Version 3.0      Revision Date: 15.01.2018      SDS Number: 12359      Date of last issue: -  
Date of first issue: 15.01.2018

---

### 11.9 STOT - repeated exposure

Not classified based on available information.

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Exposure routes: Oral

Target Organs: Stomach

Remarks: Repeated exposure may produce adverse effects.

These effects are derived from studies in animals.

Remarks: Common side effects reported from patients include headache, gastrointestinal disorders, sinusitis and respiratory infection.

May cause effects as described under single exposure.(STOT)

### 11.10 Aspiration toxicity

Not classified based on available information.

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

No data available

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Product:

##### **Ecotoxicology Assessment**

Chronic aquatic toxicity : Harmful to aquatic life with long lasting effects.  
Remarks: Information refers to  
Omeprazole sodium

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Toxicity to fish : LC50 (Danio rerio (zebra fish)): 42 mg/l  
Exposure time: 96 H  
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
aquatic invertebrates : Exposure time: 48 H  
Method: OECD Test Guideline 202

Toxicity to algae : ErC50 (green algae): > 76 mg/l  
Exposure time: 72 H  
Method: OECD Test Guideline 201

NOEC (green algae): 1.8 mg/l  
Exposure time: 72 H  
Method: OECD Test Guideline 201

Toxicity to fish (Chronic : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l



Version 3.0      Revision Date: 15.01.2018      SDS Number: 12359      Date of last issue: -  
Date of first issue: 15.01.2018

---

toxicity)      Exposure time: 32 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : NOEC (Sewage sludge organisms): 100 mg/l  
Exposure time: 3 H  
Test Type: Respiration inhibition

### Persistence and degradability

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Biodegradability : Result: Not rapidly biodegradable  
Biodegradation: < 60 %  
Method: OECD Test Guideline 301C

### Bioaccumulative potential

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Bioaccumulation : Remarks: The substance has low potential for bioaccumulation.

### Mobility in soil

#### Components:

##### **Esomeprazole Magnesium Trihydrate:**

Mobility : Remarks: Water solubility  $\geq 1$  mg/l.

Distribution among environmental compartments : Remarks: No information available.

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Disposal should be in accordance with local, state or national legislation.  
Waste, even small quantities, should never be poured down drains, sewers or water courses.  
Dispose of contents/ container to an approved incineration plant.

Contaminated packaging : Empty container will retain product residue. Observe all hazard precautions.

# SAFETY DATA SHEET



Version            Revision Date:            SDS Number:            Date of last issue: -  
3.0                15.01.2018                12359                Date of first issue: 15.01.2018

---

## SECTION 14. TRANSPORT INFORMATION

Not classified as dangerous in the meaning of transport regulations.

---

## SECTION 15. REGULATORY INFORMATION

### **Safety, health and environmental regulations/legislation specific for the substance or mixture**

In order to comply with legal duties it is necessary to consult local and national legislation.

Standard for the Uniform            : No poison schedule number allocated  
Scheduling of Medicines and  
Poisons

Prohibition/Licensing Requirements            : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

### **The components of this product are reported in the following inventories:**

REACH    : Not listed

DSL    : This product contains the following components that are not on the Canadian DSL nor NDSL.

Esomeprazole Magnesium            217087-09-7  
Trihydrate

AICS    : Not listed

ENCS    : Not listed

ISHL    : Not listed

IECSC    : Not listed

TCSI    : Not listed

TSCA    : Not On TSCA Inventory

Version	Revision Date:	SDS Number:	Date of last issue: -
3.0	15.01.2018	12359	Date of first issue: 15.01.2018

**SECTION 16. OTHER INFORMATION****Full text of other abbreviations**

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; CPR - Controlled Products Regulations; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

**Further information**

Revision Date	:	15.01.2018
Other information	:	The Safety Data Sheet has been updated to the SAP EH&S Standard template., This update affects all Sections of the Safety Data Sheet., Minor changes:., 2, 6, 8, 13
Date format	:	dd.mm.yyyy
ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
AU OEL	:	Australia. Workplace Exposure Standards for Airborne Contaminants.
ACGIH / TWA	:	8-hour, time-weighted average
AU OEL / TWA	:	Exposure standard - time weighted average

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the

# SAFETY DATA SHEET

AstraZeneca 

 MedImmune

Version	Revision Date:	SDS Number:	Date of last issue: -
3.0	15.01.2018	12359	Date of first issue: 15.01.2018

---

specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

AU / EN